2-isopropylaminothiophene | 203730-55-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-isopropylaminothiophene
• 英文别名: N-(1-Methylethyl)-2-thiophenamine；N-propan-2-ylthiophen-2-amine
• CAS: 203730-55-6
• 化学式: C₇H₁₁NS
• 分子量: 141.237
• InChiKey: SRCBAXAZDJXMLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  40.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-噻吩基锂 、 N-isopropyl-O-(trimethylsilyl)hydroxylamine 在 CuCN 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以65%的产率得到2-isopropylaminothiophene
  参考文献：
  名称：

  A General and Convenient Procedure for the Synthesis of N-Alkylarylamines and N-Alkylheteroarylamines by Electrophilic Amination of Cuprates with N-Alkylhydroxylamines

  摘要：

  DOI：

  10.1021/jo981412h

文献信息

• Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor
  申请人：——

  公开号：US20030225097A1

  公开（公告）日：2003-12-04

  Compounds of formula (I): 1 wherein: X is a group of formula (A) or (B): 2 and R 1 , R 2 , R 3 , R 4 , n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being are also described.

  式(I)的化合物： 其中： X是式(A)或(B)的基团： 而R1、R2、R3、R4、n、x、y和z的定义如所述。 还描述了它们的制备过程以及它们在治疗由神经肽Y5受体介导的疾病中的用途，如在温血动物，如人类中的用途。
• Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor
  申请人：Block Howard Michael

  公开号：US20050209233A1

  公开（公告）日：2005-09-22

  Compounds of formula (I): wherein: X is a group of formula (B): and R 1 , R 2 , R 4 , n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being, are also described.

  本文描述了化学式（I）的化合物：其中X是化学式（B）的基团，并且R1、R2、R4、n、x、y和z的定义如所述。还描述了它们的制备过程以及它们在治疗温血动物（如人类）中由神经肽Y5受体介导的疾病中的应用。
• S-SUBSTITUTED N-1- (HETERO)ARYL ALKYL-N - (HETERO)ARYL ALKYLYSOTHIOCARBAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHYSIOLOGICALLY ACTIVE S-SUBSTITUTED N-1- (HETERO )ARYL ALKYL-N - (HETERO)ARYL ALKYLYSOTHIOCARBAMIDES,A PHARMACEUTICAL COMPOUND AND CURING METHOD
  申请人：Institut Fiziologicheski Aktivnykh Veschestv Rossiyskov Akademii Nauk

  公开号：EP1577294A1

  公开（公告）日：2005-09-21

  The invention relates to s-substituted N-1-[(hetero)aryl]alkyl-N-1-[(hetero)aryl]alkylysothio-carbamides and the physiologically active salts and bases thereof, embodied in the form of racemic mixtures (or stereoisomer mixture) or individual optical isomers. The specific physiological activity of said compounds makes it possible to use them in the form of molecular tools. Said invention also relates to Pharmaceutical compositions, containing said compounds and to a method for preventing and curing various diseases including neurodegenerative diseases as, for example Alzheimer's disease (AD). The pharmacological effect of said compounds is based on the combined cognitive-stimulating and neuroprotective action thereof, which is produced by acting on chemo-controlled calcium channels of neurone membranes, in particular the neurones regulated by glutamate receptors of the central neural system (CNS).

  本发明涉及 s-取代的 N-1-[(杂)芳基]烷基-N-1-[(杂)芳基]烷基硫代氨基甲酸酯及其具有生理活性的盐和碱，以外消旋混合物（或立体异构体混合物）或单个光学异构体的形式体现。上述化合物的特殊生理活性使其有可能以分子工具的形式使用。本发明还涉及含有上述化合物的药物组合物，以及预防和治疗各种疾病（包括神经退行性疾病，如阿尔茨海默病（AD））的方法。所述化合物的药理作用基于其刺激认知和保护神经的综合作用，这种作用是通过作用于神经元膜的化学控制钙通道产生的，特别是受中枢神经系统（CNS）谷氨酸受体调节的神经元。
• Methods to treat lymphoplasmacytic lymphoma
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10597387B2

  公开（公告）日：2020-03-24

  The present invention provides compounds of any one of Formulae (I) to (V) (e.g., compounds of any one of Formulae (I-1) to (I-9)), and methods for treating Waldenström's macroglobulinemia (WM) and other B cell neoplams in a subject using the compounds. The methods comprise administering to a subject in need thereof an effective amount of the compounds. Also provided are methods to treat B cell neoplasms using the compounds in combination with inhibitors of Bruton's tyrosine kinase (BTK), interleukin-1 receptor-associated kinase 1 (IRAK1), interleukin-1 receptor-associated kinase 4 (IRAK4), bone marrow on X chromosome kinase (BMX), phosphoinositide 3-kinase (PI3K), transforming growth factor b-activated kinase-1 (TAK1), and/or a Src family kinase.

  本发明提供了式(I)至(V)中任一项的化合物(例如，式(I-1)至(I-9)中任一项的化合物)，以及使用这些化合物治疗受试者的瓦尔登斯特伦巨球蛋白血症(WM)和其他B细胞肿瘤的方法。这些方法包括向有需要的受试者施用有效量的化合物。还提供了使用化合物与布鲁顿酪氨酸激酶（BTK）、白介素-1 受体相关激酶 1（IRAK1）抑制剂联合治疗 B 细胞肿瘤的方法、白细胞介素-1 受体相关激酶 4 (IRAK4)、骨髓 X 染色体激酶 (BMX)、磷酸肌醇 3- 激酶 (PI3K)、转化生长因子 b 激活激酶-1 (TAK1)和/或 Src 家族激酶的抑制剂。
• One-Pot Syntheses of 2-N-Alkylamino-, 2-N-Phenylamino-, 2-N, N-Dialkylamino-, and 2-N-Alkyl-N-phenylaminothiophenes
  作者：Ol'ga A. Tarasova、Ludmila V. Klyba、Vladimir Yu. Vvedensky、Nina A. Nedolya、Boris A. Trofimov、Lambert Brandsma、Hermann D. Verkruijsse

  DOI：10.1002/(sici)1099-0690(199802)1998:2<253::aid-ejoc253>3.0.co;2-e

  日期：1998.2